In addition, we also observed 4 potential drug-interacted CpG sites from our results that belong to genes EGLN1, LOC283050, USP7, and RNF220. Previous study shows that the inhibition of EGLN1 improves the glucose and lipid metabolism, and protects against obesity and metabolic dysfunction [14]. This evidence concerns the gene RNF220 and obesity disorder.